GILD Stock Dives On COVID-19 Treatment

Gilead Studies Are Still In The Wings

The results of a randomized study comparing the coronavirus treatment to a placebo will be key, Evercore ISI analyst Umer Raffat said in a report. He compared the Financial Times report on the China study and the Stat News report on the compassionate-use results.

The publications drew opposite conclusions.

"I think the truth is somewhere in the middle," Raffat said. "The point on exact timing of starting remdesivir is key. It's the most important driver of (effectiveness). In fact, this is a principle in antivirals for acute infection: The earlier you start, the better the (effectiveness)."

Gilead's Parsey noted the ongoing Phase 3 tests aim to determine which patients could benefit from the coronavirus treatment. They also determine when to get treatment and for how long.

The company expects to have the results of its test in severe patients later this month. The results of the test in moderate patients should follow in May.

So, Don't give up!!!